
|Videos|July 19, 2017
Utilizing Genomic Assays for Decision Making in Early Stage Breast Cancer
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the utility of molecular signatures in managing early-stage breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at SABCS 2025
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
4
Considering Role of PD-L1 CPS in Frontline Gastric Cancer Treatment
5








































